Skip to Content

'
Christopher J. Logothetis, M.D.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1974 University of Athens School of Medicine, Athens, Greece, MD, Medicine

Postgraduate Training

1977-1979 Fellow, The University of Texas M. D. Anderson Cancer Center, Houston, TX
1975-1977 Clinical Residency, Cook County Hospital, Chicago, IL
1974-1975 Clinical Internship, Cook County Hospital, Chicago, IL

Board Certifications

1981 Medical Oncology Subspecialty Board
1978 American Board of Internal Medicine

Experience/Service

Academic Appointments

Chief, Section of Genitourinary Medical Oncology, Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1986-1993

Endowed Positions

Roy M. and Phyllis Gough Huffington Clinical Research in Urologic Oncology Distinguished Chair, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002-present
Bessie McGoldrick Professorship in Clinical Cancer Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994-present

Honors and Awards

1993-2003 CaP CURE Award
1992 Excellence in Teaching Clinical Oncology Award, UT M.D. Anderson Cancer Center Medical Oncology Fellows
1979 Clifton D. Howe Fellowship Achievement Award

Professional Memberships

American Association for Cancer Research
Member, 2001-present
American Medical Association
Member, 1978-present
American Society of Clinical Oncology
Member, 1978-present
Board of Scientific Advisors
Board Member, 2001-present
CaP CURE Foundation Board of Directors
Board Member, 2003-present
Harris County Medical Society
Member, 1978-present
Texas Medical Association
Member, 1978-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 7/10/2008. PMID: 18618013.
2. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/15/2008. PMID: 18559590.
3. Logothetis CJ, Millikan R. Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol 26(15):2423-4, 5/20/2008. PMID: 18487561.
4. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 5/2008. PMCID: PMC2562662.
5. Logothetis CJ. Strategy for the application of therapy in prostate cancer. Adv Exp Med Biol 617:193-9, 5/2008. PMID: 18497043.
6. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: Key to the effective treatment of prostate cancer. Clin Cancer Res 14(6):1599-602, 3/2008. PMID: 18347159.
7. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 11/2007.
8. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S. Meta-analysis of estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: meta-analysis of individual patient data. Lancet Oncol 8(11):994-1000, 11/2007.
9. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27(5):596-603, 8/2007. PMID: 17700537.
10. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells. Cancer Res 67(14):6544-8, 7/2007. PMID: 17638862.
11. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer (Review). Cancer Immun 7:10 (Review), 6/2007. PMID: 17591743.
12. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med, 4/2007. PMID: 17427204.
13. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13:1224-31, 2/2007. PMID: 17317833.
14. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 4:1059-70, 11/2006. PMID: 17112453.
15. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25:6015-25, 9/2006. PMID: 16682954.
16. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ. Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression. J Biol Chem 281(35):25134-42, 9/2006. PMID: 16798743.
17. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 2:144-9, 9/2006. PMID: 17026803.
18. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98(11):783-93, 6/2006. PMID: 16757703.
19. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 11/2005. PMID: 16258090.
20. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889-94, 10/2005. PMID: 16203779.
21. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, 7/2005. PMID: 16024620.
22. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, 3/2005. PMID: 15799828.
23. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21-8, 2005. PMID: 15630412.
24. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, 11/2004. PMID: 15533897.
25. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10(20):6770-8, 10/2004. PMID: 15501953.
26. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22(19):3868-76, 10/2004. PMID: 15302906.
27. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 9/2004. PMID: 15264247.
28. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-903, 9/2004. PMID: 15517894.
29. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 64(15):5036-43, 8/2004. PMID: 15289299.
30. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22(16):3323-9, 8/2004. PMID: 15310776.
31. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/2004. PMID: 15169797.
32. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 31:24-9, 4/2004. PMID: 15176001.
33. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 4/2004. PMID: 15102659.
34. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279(18):19191-200, 4/2004. PMID: 14985354.
35. Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene 23(9):1712-23, 3/2004. PMID: 14647426.
36. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 1/2004. PMID: 14744752.
37. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 2004. PMID: 14665863.
38. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, 9/2003. PMID: 14670540.
39. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, 3rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 21(5):878-83, 3/2003. PMID: 12610188.
40. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 33(1):20-6, 2003. PMID: 12613384.
41. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, 2003. PMID: 12684123.

Grant & Contract Support

Title: 3T Perflurocarbon-filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate (CT)
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Principal Investigator: Choi
Duration: 1/8/2007 - 2/7/2010
 
Title: Marcus Foundation Agreement (PP-5)
Funding Source: Marcus Foundation
Role: Co-Investigator
Duration: 7/10/2006 - 7/9/2009
 
Title: Novel Anti-PSMA Antibody-Based Paclitaxel Copolymer Prodrugs for Intraprostatic Treatment of Localized Prostatic Carcinoma
Funding Source: US Department of Defense
Role: Co-Investigator
Principal Investigator: Jim Klostergaard, M.D.
Duration: 9/23/2004 - 10/22/2007
 
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Scott Lippman, M.D.
Duration: 7/26/2004 - 12/31/2009
 
Title: Prostate Cancer Foundation Clinical Research Consortium
Funding Source: Prostate Cancer Foundation
Role: Principal Investigator
Duration: 9/1/2002 - 12/31/2008
 
Title: The Clinical Development of Thalidomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 9/28/2001 - 10/22/2007
 
Title: The University of Texas M. D. Anderson SPORE in Prostate Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/1/2001 - 12/31/2007
 
Title: Cancer Center Support (CORE) Grant-RP-16-Prostate and Genitourinary Program
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/1978 - 6/30/2013

Last updated: 8/26/2009